Further safety measures will be introduced for montelukast, a drug used for the treatment of asthma, to ensure patients are informed of the risk of neuropsychiatric reactions, following a safety review. In a statement, published on 29 April 2024, alongside a drug safety update outlining new safety measures, the Medicines and Healthcare products Regulatory Agency … Continue reading Montelukast will carry ‘more prominent warnings’ of neuropsychiatric reactions